scholarly journals Rare lung cancers—Primary pulmonary leiomyosarcoma: A case report

2021 ◽  
Author(s):  
Laurenz Nagl ◽  
Andreas Seeber ◽  
Gerlig Widmann ◽  
Katja Schmitz ◽  
Herbert Maier ◽  
...  
Keyword(s):  
Case Report ◽  
Lymph Node ◽  
Tumour Size ◽  
Lymph Node Status ◽  
R0 Resection ◽  
Interdisciplinary Management ◽  
Curative Surgery ◽  
Lung Cancers ◽  
Tumour Control ◽  
Complete Tumour

SummaryPrimary pulmonary sarcomas (PPS) are rare mesenchymal lung cancers, which do not present clinically or radiological different to lung carcinomas. Definite PPS diagnosis can only be made by histological analysis and detailed staging examinations in order to exclude a secondary pulmonary malignancy such as metastatic soft tissue sarcoma or another solid tumour. Here we present the case of a 66-year-old woman with a pulmonary mass infiltrating the diaphragm and the mediastinal adipose tissue, which was identified as leiomyosarcoma. The patient received curative surgery with complete tumour R0 resection. The prognosis of PPS is defined by tumour size, lymph node status and histological grading. Surgery is the mainstay of therapy and there is no definitive indication for adjuvant therapy for R0-resected and lymph-node-negative patients like in our case. However, multimodal therapy approaches such as (neo)adjuvant chemo- and radiotherapy can contribute to improving locoregional tumour control, which is the most important prognostic factor. With our case report we want to raise awareness for pulmonary sarcomas as a relevant proportion of rare lung cancers which have to be kept in mind during the differential diagnosis. Moreover, we aim to discuss the complex and individual interdisciplinary management.

Role of adjuvant therapy after R0 resection for patients with distal cholangiocarcinoma.

2016 ◽  
Vol 34 (4_suppl) ◽  
pp. 355-355
Author(s):  
Young Saing Kim ◽  
In Gyu Hwang ◽  
Song-ee Park ◽  
Eun Young Kim ◽  
Jung Hun Kang ◽  
...  
Keyword(s):  
Lymph Node ◽  
Adjuvant Therapy ◽  
Lymph Nodes ◽  
Multivariable Analysis ◽  
Cox Proportional Hazards Model ◽  
Lymph Node Status ◽  
R0 Resection ◽  
Distal Cholangiocarcinoma ◽  
Positive Lymph Nodes

355 Background: There is still debated regarding the optimal treatment strategy in cholangiocarcinoma after curative resection. The aim of this study was to analyze the role of adjuvant therapy in R0-resected distal cholangiocarcinoma. Methods: We retrospectively reviewed the medical records of patients who underwent R0 resection for distal cholangiocarcinoma between January 2001 and December 2013 at six cancer centers in Korea. Adjuvant therapy consisted of chemotherapy (CT), chemoradiotherapy (CRT), or radiotherapy (RT). Multivariable Cox proportional hazards model was used to identify prognostic factors for overall survival (OS). Results: A total of 158 patients were included in the analysis; 47 patients (29.7%) had lymph node involvement. Fifty-six patients (35.4%) received adjuvant therapy (CT/CRT/RT: 27/20/9, respectively). Patients with advanced TNM stage (p = 0.001), T3/T4 disease (p = 0.009), positive lymph nodes (p = 0.052) and elevated CA 19-9 (p = 0.071) were more likely to receive adjuvant therapy. The effect of adjuvant therapy varied according to the treatment modality. Multivariable analysis showed a significant improvement in OS with CRT (Hazard ratio (HR) 0.25, 95% CI 0.08-0.83, p = 0.024) and CT (HR 0.21, 95% CI 0.08-0.53, p = 0.001). However, RT alone was associated with shorter OS (HR 2.38, p = 0.040), along with T3/T4 disease (HR 2.12, p = 0.012) and positive lymph nodes (HR 2.30, p = 0.008). In the subset analysis according to lymph node status, adjuvant therapy not including RT alone was associated with a significant OS advantage both in node-negative patients (median, 103.3 vs. 54.9 months, p = 0.037) and node-positive patients (not reached vs. 22.6 months, p = 0.013). Conclusions: Our results showed that patients receiving adjuvant CT or CRT had significant improvement in OS. In addition, the benefit of adjuvant therapy (except RT alone) was observed even in patients with negative lymph nodes.

EP.TH.63Predictive significance of tumour size in patients undergoing curative surgery for colorectal cancers: Retrospective cohort study

2021 ◽  
Vol 108 (Supplement_7) ◽  
Author(s):  
Shahab Hajibande ◽  
Mohammed Barghash ◽  
Asaf Khan ◽  
Baqar Ali
Keyword(s):  
Overall Survival ◽  
Lymph Nodes ◽  
Tumour Size ◽  
Venous Invasion ◽  
Lymphocytic Infiltration ◽  
R0 Resection ◽  
Curative Surgery ◽  
Specimen Length ◽  
Rectal Cancers ◽  
Positive Lymph Nodes

Abstract Aims Evaluating predictive significance of tumour size in patients undergoing curative colorectal cancer surgery. Methods Patients undergoing curative surgery (77.6% Laparoscopic) for colorectal cancer by a single surgeon between January 2013 and January 2020 inclusive. Linear/binary logistic regression analyses were modelled to assess whether colonic or rectal tumour size could predict R0 resection, specimen length, length >120mm, number of harvested lymph nodes, >12 harvested lymph nodes, number of positive lymph nodes, lymphocytic infiltration, venous invasion, and overall survival. Results Total of 192 patients (124 colon and 68 rectal cancers) were eligible. In colon cancer patients, tumour size was independent predictor of the number of harvested lymph nodes (P < 0.001), the number of positive lymph nodes (P = 0.001), and lymphocytic infiltration (P = 0.009). It did not predict R0 resection (P = 0.563), specimen length (P = 0.111), specimen length >120mm (P = 0.186), >12 harvested lymph nodes (P = 0.145), venous invasion (P = 0.103), 5-year overall survival (P = 0.543). Independent predictor in rectal cancers was the number of harvested lymph nodes (P < 0.001), and the number of positive lymph nodes (P < 0.001). It did not predict R0 resection (P = 0.108), specimen length (P = 0.774), specimen length >120mm (P = 0.405), >12 harvested lymph nodes (P = 0.069), lymphocytic infiltration (P = 0.912), venous invasion (P = 0.105), and 5-year overall survival (P = 0.413). Conclusions Current study results suggest tumour size alone may not have a significant predictive value in terms of oncological or survival outcomes in patients undergoing curative surgery for cancer of colon or rectum.

scholarly journals Predictive Factors of Lymph Node Status in Small Peripheral Non-small Cell Lung Cancers: Tumor Histology is Better Than Subcentimeter in Size

CHEST Journal ◽  
2012 ◽  
Vol 142 (4) ◽  
pp. 36A
Author(s):  
Yang Zhang ◽  
Haiquan Chen ◽  
Jiaqing Xiang ◽  
Yawei Zhang ◽  
Yihua Sun ◽  
...  
Keyword(s):  
Lymph Node ◽  
Predictive Factors ◽  
Small Cell ◽  
Lymph Node Status ◽  
Small Cell Lung ◽  
Lung Cancers ◽  
Tumor Histology ◽  
Node Status ◽  
Better Than

scholarly journals Evaluation and Correlation of Clinicopathological Parameters of Oral Squamous Cell Carcinoma of Gingivobuccal Sulcus with Lymph Node Status - A Retrospective Institutional Analysis in Navi Mumbai

2021 ◽  
Vol 10 (30) ◽  
pp. 2294-2299
Author(s):  
Akash Shegaonkar ◽  
Shilpa Patel ◽  
Niharika Swain ◽  
Jigna Pathak ◽  
Rashmi Hosalkar ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Lymph Node ◽  
Oral Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Perineural Invasion ◽  
Tumour Size ◽  
Clinicopathological Parameters ◽  
Lymph Node Status ◽  
Node Status

BACKGROUND Mortality and Morbidity rates in the patients diagnosed with oral cancers remain static despite availability of advanced diagnostic and treatment modalities. For improving the survival status of the patients, a thorough understanding of the factors that predicts the progression of oral cancer is necessary to determine appropriate line of treatment. To do so in practise, critical knowledge regarding the prognostic factors that has high sensitivity holds immense importance. For determination of prognosis in oral cancer patients, clinical and histopathological parameters are widely used for assessment of treatment strategies. The primary objective of this study was to determine the clinical and histopathological prognostic factors in patients of oral squamous cell carcinoma of gingivobuccal sulcus (GBSSCC) treated by surgical intervention (neck dissection). METHODS Histopathological evaluation of archived samples of 60 GBSSCC patients which were treated by surgical intervention (Neck Dissection) in the time period from January 2011 to December 2020. Recurrent cases were excluded. Clinicopathological parameters such as age, sex, habit, tumour site, tumour size, tumour differentiation, depth of invasion, bone invasion, muscle invasion, perineural invasion & extracapsular spread were evaluated & then correlated with lymphnode status. RESULTS Among all the parameters, variables like habit (tobacco use) (P = 0.045), tumour size (P = 0.003), perineural invasion (P = 0.000) emerged as independent prognosticators and significantly correlated to the lymph node status of the patients. CONCLUSIONS This analysis suggests that habit, tumour size, perineural invasion to be consistent, easy to assess and reliable independent prognosticators which are significantly correlated to the lymph node status. To conclude, it is of paramount importance to include the aforementioned prognosticators in histopathological reports for the prediction of clinical outcome and archiving of valued data for future analysis. KEY WORDS Oral Squamous Cell Carcinoma, Gingivobuccal sulcus, Lymph Node Status, ClinicoPathological Prognosticators

scholarly journals Association of HER-2 Expression with Age, Tumour Size, Grade, Differentiation and Lymph Node Deposit in Patients with Breast Cancer

2020 ◽  
Vol 32 (2) ◽  
pp. 14-21
Author(s):  
Sharmin Ferdousi ◽  
Shah Md Badruddoza ◽  
SM Asafuddullah
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Hormone Receptors ◽  
Tumour Size ◽  
Breast Cancer Incidence ◽  
Age Groups ◽  
Lymph Node Status ◽  
Cross Sectional ◽  
Size Grade ◽  
Her 2

Breast Cancer incidence is increasing, but its mortality has started to decrease. The existence of strong reliable prognostic and predictive factors is of utmost importance to the practicing clinician. Some factors are only prognostic such as age, tumor size, and lymph node status, while others are both prognostic and predictive such as hormone receptors and human epidermal receptor 2 (HER’s-2) status. This study was done to see the association of HER-2 positivity with age, tumour size, grade, differentiation and lymph node deposit in breast cancer patient. A cross-sectional type of descriptive study was conducted among 50 patients. Patient age range is from 22 to 64 years (mean 42.64 ± 10.26 years). Tumour size ranged from 1 to 8 cm (mean 4.39 ± 1.564cm). Well differentiated tumour was 20, moderately differentiated tumour was 18 cases and poorly differentiated was 12 cases. HER-2/neu negative included 35(70%) cases and positive included 15(30%) cases. In this study it was found that the association between age groups and tumour differentiation with HER-2/neu status was statistically significant (p= <0.05). TAJ 2019; 32(2): 14-21

Additional prognostic value of OncoMasTR multigene prognostic signature to clinicopathological information in patients with HR-positive, HER2-negative, lymph node-negative breast cancer from the TAILORx Tissue Bank, Ireland.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. 535-535
Author(s):  
Darran O'Connor ◽  
Catherine Margaret Kelly ◽  
John Crown ◽  
Niamh Russell ◽  
Stephen Barron ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Prognostic Value ◽  
Tumour Size ◽  
Tissue Bank ◽  
Prognostic Index ◽  
Recurrence Score ◽  
Lymph Node Status ◽  
Prognostic Information ◽  
Prognostic Performance

535 Background: Multigene prognostic signatures (MGPS) can identify early stage breast cancer patients who may require less aggressive treatment. To be clinically useful, MGPSs must provide additional prognostic information to clinicopathological information routinely used by clinicians. The OncoMasTR MGPS was discovered via a novel bioinformatic transcriptional network analysis. OncoMasTR consists of genes – Master Transcription Regulators (MTRs) – that regulate previously known prognostic genes and have identified functional roles in several hallmarks of cancer including proliferation, invasion and metastasis. The OncoMasTR Molecular Score (OM) consists of just 3 MTRs. The OncoMasTR Risk Score (OncoMasTR) combines OM with lymph node status and tumour size, and categorises patients as low or high risk. The OncoMasTR Test has been analytically and clinically validated. Methods: MTR expression was measured by RT-qPCR in tissue from 404 patients enrolled in an independent translational trial (NCT02050750) that collected tissue and clinical data from patients enrolled in TAILORx in Ireland. OM, OncoMasTR and Oncotype DX Recurrence Score (RS) were compared on the additional prognostic value they provided to Ki67, Nottingham Prognostic Index (NPI) and other clinicopathological information for distant recurrence (DR) and invasive disease (ID). Results: OM (LRχ2 = 20.3, p < 0.00001, c-index = 0.84) and OncoMasTR (LRχ2 = 22.6, p < 0.00001, c-index = 0.85) were significantly prognostic, and more prognostic than RS (LRχ2 = 8.4, p = 0.004, c-index = 0.73) for DR. OM and OncoMasTR provided more additional prognostic information than RS to Ki67, NPI, tumour size, tumour grade, and age for DR. Similar results were found when OM, OncoMasTR and RS were compared on prognostic performance for ID. Conclusions: OM and OncoMasTR were significantly prognostic for DR and ID and added significant prognostic value to Ki67, NPI, and other clinicopathological information. Furthermore, OM and OncoMasTR showed superior prognostic performance to RS.

P120 MULTIMODAL THERAPY IN ESOPHAGEAL CANCER BEYOND CLINICAL TRIAL: SINGLE CENTRE EXPERIENCE

2019 ◽  
Vol 32 (Supplement_2) ◽  
Author(s):  
S Giacopuzzi ◽  
L Alberti ◽  
J Weindelmayer ◽  
Pasqual C A De ◽  
L Torroni ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Lymph Node ◽  
Clinical Practice ◽  
Neoadjuvant Treatment ◽  
Neoadjuvant Chemoradiotherapy ◽  
Real Life ◽  
Pathological Response ◽  
Lymph Node Status ◽  
R0 Resection ◽  
Treatment Type

Abstract Aim investigate factors influencing the choice of neoadjuvant treatment type in the real world, analyzing our single high-volume center experience. Background & Methods The neoadjuvant chemoradiotherapy is the standard of care for esophageal cancer [1-2]. This consensus stems from the results of CCT performed on highly selected patients. However, the best treatment for non-selected patients remains unclear. In our clinical practice the treatment considered the goal standard is a TCF with 50GyRT [3-4-5], which showed an R0 resection rate of 88% and 5 y OS of 43%, better than CROSS trial. Despite these results, since 2012 not all patients underwent the same ideal treatment. We analyzed a real life patients group, that from the oncological point of view, they would be treated with our protocol in an intention to treat setting. Results From 2012 to 2017, 244 patients were treated. Analyzing retrospectively our data, it emerges that we have chosen the therapeutic strategy based on patient's characteristics: those aged over 75 yrs or with severe comorbidities were addressed to a “weakened” treatment: 37 with chemotherapy, 24 with radiotherapy and 55 with concomitant chemoradiotherapy different from our protocol. 125 with our protocol. Further selection involved lymph node status and patients with lymph node involvement (>N2 were referred to chemotherapy. The results confirmed that the protocol achieves better results in pathological response (pT0N0 in protocol 40,8% vs 18.2% in standard chemoradiotherapy – p value <0.001) and overall survival, especially for squamous hystotype. Regarding adenocarcinoma, chemotherapy and our protocol obtain good results for OS, although they differ on pathological response (pCR: 40.8% vs 5.4%). Most of the patients referred to chemotherapy had nodes involvement at the diagnosis (88.9%) and pathological response on nodes was significantly worse than protocol (pN0: 26.7% in chemotherapy vs 77.5%), however survival was similar between the two treatments. Conclusion Chemoradiotherapy is currently the gold standard of treatment but it cannot be consider the only treatment, especially for real life patients, less ideal but still requiring treatment. Clinical trials are certainly useful in providing information on highly selected patients, but clinical practice must consider patients whose conditions require tailored treatment.

Predictive Factors of Lymph Node Status in Small Peripheral Non-small Cell Lung Cancers: Tumor Histology is More Reliable

2012 ◽  
Vol 20 (6) ◽  
pp. 1949-1954 ◽  
Author(s):  
Yang Zhang ◽  
Yihua Sun ◽  
Lei Shen ◽  
Yuan Li ◽  
Jiaqing Xiang ◽  
...  
Keyword(s):  
Lymph Node ◽  
Predictive Factors ◽  
Small Cell ◽  
Lymph Node Status ◽  
Small Cell Lung ◽  
Lung Cancers ◽  
Tumor Histology ◽  
Node Status

scholarly journals Clinicopathological Significance of Mesothelin Expression in Invasive Breast Cancer

2012 ◽  
Vol 40 (3) ◽  
pp. 909-916 ◽  
Author(s):  
L Wang ◽  
Z Niu ◽  
L Zhang ◽  
X Liu ◽  
X Wang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Overall Survival ◽  
Lymph Node ◽  
Breast Carcinoma ◽  
Invasive Breast Cancer ◽  
Tumour Size ◽  
Prognostic Significance ◽  
Growth Factor Receptor ◽  
Tumour Cells ◽  
Lymph Node Status

OBJECTIVES: This study evaluated the expression profile of the mesothelin ( MSLN) gene and its prognostic significance in breast cancer. METHODS: To evaluate the diagnostic and prognostic significance of mesothelin, immunohistochemistry was used to assess the level of mesothelin protein in surgically resected, formalin-fixed, paraffin-embedded invasive breast carcinoma specimens. Associations between mesothelin and other biomarkers, including oestrogen receptor (OR), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2/neu), were also evaluated. RESULTS: A total of 182 breast carcinoma specimens were included. Mesothelin protein was present in the membrane of malignant cells. There was correlation between the presence of mesothelin in tumour cells and tumour infiltration of the lymph node. There was no correlation between the presence of mesothelin and HER2/neu protein, OR and PR in tumour cells. Mesothelin levels were significantly associated with decreased overall survival. CONCLUSIONS: Lymph node status, tumour size, HER2/neu and mesothelin protein levels in breast cancer cells were independent prognostic factors. Mesothelin could be useful as a prognostic marker of overall survival in invasive breast cancer.

Sign in / Sign up

Export Citation Format

Share Document